Compare GORO & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GORO | NYXH |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.0M | 190.6M |
| IPO Year | 2010 | 2021 |
| Metric | GORO | NYXH |
|---|---|---|
| Price | $1.13 | $3.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.75 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 1.8M | 55.7K |
| Earning Date | 03-18-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,759,000.00 | N/A |
| Revenue This Year | $9.04 | $97.32 |
| Revenue Next Year | $93.07 | $241.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 51.78 | N/A |
| 52 Week Low | $0.34 | $3.05 |
| 52 Week High | $1.87 | $11.87 |
| Indicator | GORO | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 33.26 | 28.50 |
| Support Level | $0.79 | N/A |
| Resistance Level | $1.18 | $5.02 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 15.57 | 4.46 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.